» Articles » PMID: 38321552

Peroxiredoxin 3 Regulates Breast Cancer Progression Via ERK-mediated MMP-1 Expression

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2024 Feb 6
PMID 38321552
Authors
Affiliations
Soon will be listed here.
Abstract

Peroxiredoxin 3 (PRDX3), a mitochondrial hydrogen peroxide scavenger, is known to be upregulated during tumorigenesis and cancer progression. In this study, we provide evidence for the first time that PRDX3 could regulate cellular signaling pathways associated with Matrix Metalloproteinase-1 (MMP-1) expression and activity in breast cancer progression. We show that shRNA-mediated gene silencing of PRDX3 inhibits cell migration and invasion in two triple-negative breast cancer cell lines. Reciprocal experiments show that PRDX3 overexpression promotes invasion and migration of the cancer cells, processes which are important in the metastatic cascade. Notably, this phenomenon may be attributed to the activation of MMP-1, which is observed to be upregulated by PRDX3 in the breast cancer cells. Moreover, immunohistochemical staining of breast cancer tissues revealed a positive correlation between PRDX3 and MMP-1 expression in both epithelial and stromal parts of the tissues. Further pathway reporter array and luciferase assay demonstrated that activation of ERK signaling is responsible for the transcriptional activation of MMP-1 in PRDX3-overexpressed cells. These findings suggest that PRDX3 could mediate cancer spread via ERK-mediated activation of MMP-1. Targeted inhibition of ERK signaling may be able to inhibit tumor metastasis in triple-negative breast cancer.

Citing Articles

Detection of transmembrane protein 100 in breast cancer: Correlation with malignant progression and chemosensitivity.

Liu X, Zhang G, Zhao L Cytojournal. 2025; 21:65.

PMID: 39917003 PMC: 11801651. DOI: 10.25259/Cytojournal_107_2024.


Comparison of Microalgae and Lipid Extracts Effects on UVA-Induced Changes in Human Skin Fibroblasts Proteome.

Atalay Ekiner S, Gegotek A, Domingues P, Domingues M, Skrzydlewska E Mar Drugs. 2024; 22(11).

PMID: 39590789 PMC: 11595653. DOI: 10.3390/md22110509.

References
1.
Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

2.
Wang X, Wang H, Li X . Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumour Biol. 2013; 34(4):2275-81. DOI: 10.1007/s13277-013-0769-0. View

3.
Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J . GOBO: gene expression-based outcome for breast cancer online. PLoS One. 2011; 6(3):e17911. PMC: 3061871. DOI: 10.1371/journal.pone.0017911. View

4.
Abba M, Patil N, Allgayer H . MicroRNAs in the Regulation of MMPs and Metastasis. Cancers (Basel). 2014; 6(2):625-45. PMC: 4074795. DOI: 10.3390/cancers6020625. View

5.
Li X, He P, Wang X, Zhang S, Devejian N, Bennett E . Sulfiredoxin-1 enhances cardiac progenitor cell survival against oxidative stress via the upregulation of the ERK/NRF2 signal pathway. Free Radic Biol Med. 2018; 123:8-19. PMC: 5999586. DOI: 10.1016/j.freeradbiomed.2018.05.060. View